Prof. Eamonn M.M. Quigley
Prof. Eamonn Quigley is Chief of the Division of Gastroenterology and Hepatology and Professor of Medicine at the Institute for Academic Medicine at Houston Methodist Hospital (Houston, USA). He is internationally known for his research on gastrointestinal motility disorders, primarily Irritable Bowel Syndrome (IBS); functional gastrointestinal disease; GastroEsophageal Reflux Disease (GERD); neurogastroenterology; the role of gut microbiota and probiotics in health and disease.
- Past President of the American College of Gastroenterology and the World Gastroenterology Organization
- Past Editor-in-Chief of the American Journal of Gastroenterology
Prof. Eamonn Quigley is Chief of the Division of Gastroenterology and Hepatology and Professor of Medicine at the Institute for Academic Medicine at Houston Methodist Hospital (Houston, USA). He is internationally known for his research on gastrointestinal motility disorders, primarily Irritable Bowel Syndrome (IBS); functional gastrointestinal disease; GastroEsophageal Reflux Disease (GERD); neurogastroenterology; the role of gut microbiota and probiotics in health and disease.
- Past President of the American College of Gastroenterology and the World Gastroenterology Organization
- Past Editor-in-Chief of the American Journal of Gastroenterology
Prof. Eamonn M.M. Quigley is David M Underwood Chair of Medicine in Digestive Disorders and Chief of the Division of Gastroenterology and Hepatology at Houston Methodist Hospital. A native of Cork, Ireland, he graduated in medicine from University College Cork. He trained in internal medicine in Glasgow (Scotland), completed a two-year research fellowship at the Mayo Clinic (USA) and trained in gastroenterology in Manchester (UK). He joined the University of Nebraska Medical Center in 1986 where he rose to become Chief of Gastroenterology and Hepatology. Returning to Cork in 1998 he served as Dean of the Medical School and as a Principal Investigator at the Alimentary Pharmabiotic Center (National University of Ireland in Cork).
He is internationally known for his research on gastrointestinal motility disorders, primarily Irritable Bowel Syndrome (IBS); functional gastrointestinal disease; GastroEsophageal Reflux Disease (GERD); neurogastroenterology (the relationship between the central nervous system and the gut); the role of gut microbiota and probiotics in health and disease. While the cause of IBS has not been clearly identified, Quigley’s clinical research suggests that an alteration of the normal gut bacteria flora may be a cause. His research team is working toward developing new biomarkers for IBS which would eventually lead to the development of new treatments. Quigley’s clinical interests focus on the use of probiotics for the treatment of IBS.
He has authored over 1000 publications and has received awards and honorary titles worldwide. He served as President of the American College of Gastroenterology and the WGO and as Editor-in-chief of the American Journal of Gastroenterology.
Houston Methodist Hospital (https://www.houstonmethodist.org/)
Weill Cornell Medical College (https://weill.cornell.edu/)
University College Cork (https://www.ucc.ie/en/)
American College of Gastroenterology (https://gi.org/)
World Gastroenterology Organisation (https://www.worldgastroenterology.org/)
Ghoshal U-C. et al.
Physician Perceptions on the Use of Antibiotics and Probiotics in Adults: An International Survey in the Asia-Pacific Area.
Front Cell Infect Microbiol. 2021 Oct 19;11:722700.
Salminen S. et al.
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics.
Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):649-667.
Sperber A-D. et al.
Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study.
Gastroenterology. 2021 Jan;160(1):99-114.e3.
Hayes P-A. et al.
Irritable bowel syndrome: the role of food in pathogenesis and management.
Gastroenterol Hepatol (NY). 2014 Mar;10(3):164-74.
Whorwell P-J. et al.
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
Am J Gastroenterol. 2006 Jul;101(7):1581-90.
O’Mahony L. et al.
Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.
Gastroenterology. 2005 Mar;128(3):541-51.
Prof. Eamonn M.M. Quigley’s Microbiota Events
Practical tools to healthcare professionals to support the patients in their daily life and relieve them from IBS chronic condition.
